5,993 Shares in TransMedics Group, Inc. $TMDX Purchased by Federated Hermes Inc.

Federated Hermes Inc. purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,993 shares of the company’s stock, valued at approximately $672,000.

Several other large investors also recently modified their holdings of TMDX. Royal Bank of Canada lifted its position in shares of TransMedics Group by 47.9% during the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after buying an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of TransMedics Group by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after acquiring an additional 868 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after acquiring an additional 86,721 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter valued at $224,000. Finally, KLP Kapitalforvaltning AS grew its holdings in shares of TransMedics Group by 3.1% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,600 shares of the company’s stock worth $884,000 after purchasing an additional 200 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Stock Up 4.2%

Shares of TMDX opened at $135.06 on Friday. The business’s fifty day moving average price is $133.12 and its two-hundred day moving average price is $124.49. The firm has a market capitalization of $4.62 billion, a price-to-earnings ratio of 54.68 and a beta of 2.06. TransMedics Group, Inc. has a 52 week low of $62.07 and a 52 week high of $156.00. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69.

Insider Activity at TransMedics Group

In related news, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the sale, the chief financial officer directly owned 15,064 shares in the company, valued at $2,103,235.68. This trade represents a 5.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Weill sold 5,000 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the sale, the director directly owned 12,134 shares of the company’s stock, valued at $1,682,257.76. This represents a 29.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 8,920 shares of company stock worth $1,257,310 over the last 90 days. Insiders own 7.00% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TMDX. Needham & Company LLC lifted their price target on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a report on Monday, December 8th. Morgan Stanley lifted their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Piper Sandler reissued an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Wall Street Zen cut TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Finally, Canaccord Genuity Group lifted their price objective on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.